Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-05-19 17:54:50 ET · period of report 2026-05-15 · accession 0002020969-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 17:54 | 2026-05-15 | RXRX | Khan Najat | CEO, Pres, Dir | F - Tax | $3.04 | -62.7K | 2.20M | -3% | -$190.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-05-15 | F | D | 62,701 | $3.04 | 2,199,384 | D | — | — | (F1) Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |